Posted on

How Pharma Supply Chain Consulting Helps Close Complex Gaps

Pharma Supply Chain Consulting Helps Close Complex Gaps

The average duration of an active drug shortage had grown to more than five years, according to the United States Pharmacopeia’s 2026 Annual Drug Shortages Report, which assessed shortages active at the end of 2025. That number alone tells you something has changed. Drug shortages may begin with a plant closure, manufacturing-quality issue, production delay or shortfall in a critical raw material. Many now persist for years because the causes are more complex than a single supplier, manufacturing site or country.

This is the environment that pharma supply chain consulting is designed to address. This article breaks down where the gaps really come from, what a consulting partner does about them, and why the solution often extends to how pharmaceutical manufacturing capacity is planned and built in the first place.

Where the Gaps Actually Show Up

Most pharmaceutical supply chains look good on paper until one link breaks. Research published by USP in 2026 found that 44% of drugs in shortage had at least one key starting material, or KSM, manufactured solely in a single country, typically China or India. This sort of concentration implies that a single export restriction, plant inspection failure, or natural disaster can affect all manufacturers relying on that one source simultaneously.

Add tariff and trade-policy volatility to that risk. A survey conducted in February 2025 by the Biotechnology Innovation Organization found that nearly 90 per cent of U.S. biotech companies relied on imported components for at least half of their FDA-approved products. For affected manufacturers, changes in trade policy can alter material costs, lead times and the commercial viability of established sourcing models.

And most companies don’t plan for this ahead of time. A 2026 Operations Outlook survey from Argon & Co surveyed more than 800 senior executives across major global markets and found that only 22% of global pharmaceutical companies were actively performing risk assessments for geopolitical threats at the end of 2025. Here’s why that matters: Supply chain gaps seldom announce themselves early. When it shows up as a stockout, the company is already reacting, not strategising.

What Pharma Supply Chain Consulting Actually Does

A good consulting partner follows a fairly consistent sequence, whether the client is a small biotech or a large manufacturer:

  1. Follow the supply chain down to the raw material level. This means examining not only API suppliers, but also the key starting materials and critical intermediates behind them, as that is often where concentration risk lies.
  2. Evaluate suppliers based on risk, not just cost. This includes single-source dependencies, geographic concentration, quality history, capacity, lead times and financial stability.
  3. Develop dual- or multiple-sourcing plans for the highest-risk inputs, supported by realistic timelines for auditing, testing, qualification and regulatory implementation.
  4. Model safety-stock requirements against working-capital constraints. Holding several months of API inventory may reduce exposure, but it can also tie up capital and introduce shelf-life, storage and material-release considerations.
  5. Link supply chain decisions to manufacturing capacity and determine whether existing facilities, expanded capacity or new facilities will be required to support diversified sourcing.

For regulated products, qualifying an alternate API source may also require an assessment of impurity profiles, physical properties, process performance, stability data and the applicable regulatory reporting pathway. An alternate supplier cannot always be introduced through a procurement decision alone.

That last point is where supply chain consulting and facility strategy start to overlap, and it’s worth spending some time on it

Connecting Supply Chain Strategy to Custom Pharma Facility Design

The strength of a diversified sourcing plan is only as strong as the manufacturing capacity and quality systems  behind it. If a company qualifies a second API supplier and its equipment, process or facility cannot accommodate the material characteristics or associated manufacturing requirements, the diversification plan may be delayed or require additional investment.

That’s what flexible pharmaceutical facility design helps address. A facility built around one process line, with no flexibility to do another formulation or a new dosage form, forces a company to be tied to its existing supplier relationships, whether it wants to be or not. A facility with modular process suites, expandable utility capacity, appropriate containment, spare electrical and automation capacity, and planned space

This link is often overlooked. The supply chain teams build the sourcing plan. Facility teams build the manufacturing infrastructure. If the two don’t talk early, the physical facility is the constraint that keeps a good sourcing strategy from working.

Why Turnkey Construction Firms Matter to Supply Continuity

When a company determines that it needs new or expanded capacity to support supply chain resilience, speed and accountability are both important. That’s where pharmaceutical turnkey construction partners come in.

One accountable partner for scale-up

With one company coordinating design, procurement, construction, installation and CQV within an integrated project scope, you remove the handoff gaps that can slow a project down. A fragmented project team with unclear ownership can add project-delivery risk at a time when a supply disruption is already affecting production, inventory or commercial commitments.

Faster time to qualified capacity

Off-site modular construction methods available through selected pharmaceutical turnkey partners can compress parts of the project schedule by allowing module fabrication, site preparation and infrastructure work to progress in parallel. If you’re a company racing to qualify a new supplier and establish the manufacturing capacity required to support it, schedule coordination can affect whether additional qualified capacity is available when it is needed.

The final time to operational readiness will still depend on equipment lead times, technology transfer, site conditions, commissioning, qualification, process validation and regulatory requirements.

Energy Resilience in Modern Pharma Facilities: A Hidden Supply Chain Risk

Energy Resilience in Modern Pharma Facilities: A Hidden Supply Chain Risk

Risk in the supply chain doesn’t stop with raw materials. Energy is part of the chain too, and it’s often overlooked. Energy-price volatility, utility interruptions and disruptions to fuel or transport networks can increase manufacturing costs, affect temperature-controlled logistics and delay pharmaceutical production.

This fact should be directly included in the energy-planning strategy for a modern pharmaceutical facility. Facilities that are fully reliant on a single power source or utility configuration may carry an operational-continuity risk that resembles other forms of supply concentration. Backup generation,UPS support for critical systems, resilient utility design, on-site energy monitoring and efficient HVAC systems all provide additional protection against the types of disruption that can affect production continuity.

HVAC systems in pharmaceutical cleanrooms can be highly energy intensive because they must maintain controlled airflow, filtration, temperature, humidity and pressure relationships. However, the exact energy profile will depend on the process, cleanroom classification, utility systems and facility design.

What to Look for in Pharma Turnkey Consultants

Not all consultants or construction partners link supply chain thinking with facility planning. distinguishes partners that take an integrated approach.

  • They ask you about your sourcing strategy and future capacity requirements before they draw a single floor plan.
  • Instead of a single, fixed line, plan flexible process capacity, expandable utilities and future equipment interfaces where the business case supports them.
  • They design energy resilience from the start, not as an afterthought.
  • They have documented experience in multiple dosage forms and geographies.
  • They can demonstrate experience through previous projects where facility design supported a capacity, expansion or operational-continuity requirement.

Pharma turnkey consultants who treat facility design and supply strategy as one conversation, rather than two separate ones, are better positioned to deliver facilities that support the resilience objectives established by business and operations leadership.

Where Pharma Access Fits Into This Picture

Where Pharma Access Fits Into This Picture

Pharma Access, headquartered in Mumbai, provides pharmaceutical engineering design, procurement and supplies, construction and installation, CQV and project management services for pharmaceutical and biotechnology facilities. The company integrates engineering and execution within a coordinated project-delivery model, allowing capacity, process flexibility, utility resilience and future expansion requirements to be considered alongside facility planning.

Its Modular Mobile Facility approach also gives companies an off-site modular option for adding or developing manufacturing capacity where speed, phased expansion or constrained site conditions are important project considerations. Project suitability will depend on the dosage form, production scale, site conditions, regulatory pathway and geography.

Pharma Access does not need to replace the specialist pharma supply chain consultant in this process. Its role is to translate sourcing, capacity and resilience requirements into coordinated pharmaceutical engineering and execution strategies.

Steps to Close the Gaps

  1. Trace your supply chain back to key starting materials, not just finished API suppliers.
  2. Perform a geopolitical and tariff risk assessment at least annually.
  3. Create a facility design brief that considers future sourcing changes, not only current production.
  4. Compare pharmaceutical turnkey partners not only on price, but also on flexibility, technical capability, CQV integration, project accountability and speed.
  5. And don’t think of energy resilience as just another utility item within your supply chain risk plan.

Frequently Asked Questions

What is pharma supply chain consulting? 

It’s advisory work that charts sourcing risk across API, key starting material, supplier, manufacturing-capacity  and logistics networks and then develops diversification, inventory, and facility strategies to lower the risk of a disruption turning into a shortage.

Why do drug shortages keep lasting longer even as their total number declines? 

Many shortages are now driven by structural problems, such as geographic concentration in key starting materials, manufacturing-quality issues, limited production capacity, product discontinuations and thin profit margins that limit investment in resilience, rather than one-off events that resolve quickly once fixed.

How does facility design affect supply chain resilience? 

A facility with flexible process capacity enables a company to take advantage of a diversified sourcing plan. A rigid, single-line facility can tie a business to existing processes, equipment configurations and capacity limitations even after new ones are qualified.

Do small biotech companies need supply chain consulting, or is it only for large manufacturers? 

Small biotechs can be particularly exposed because they may operate with tighter working-capital limits and depend on a small number of suppliers, CDMOs or logistics routes. Consulting helps them prioritise which risks to address first without overspending on unaffordable safety stock or unnecessary infrastructure.

How does energy volatility connect to pharmaceutical supply chains? 

Pharmaceutical production is an energy-intensive process, and local energy interruptions or price volatility can increase production costs, disrupt critical utilities, affect cold-chain operations and delay output. This risk is reduced for facilities with backup power, resilient utility systems, energy monitoring and efficient HVAC design.

Posted on

Turnkey Construction Firms for Energy-Efficient Pharmaceutical Facilities: What to Look For

Turnkey Construction Firms for Energy-Efficient Pharmaceutical Facilities

A pharmaceutical factory does not operate like a normal factory. Cleanrooms require controlled filtered airflow, defined temperature and humidity ranges, and pressure regimes appropriate to the product, process and containment strategy. That kind of precision comes at a cost. Research published in the Journal of the International Society for Pharmaceutical Engineering, found that HVAC systems can account for between 36% and 67% of total facility energy consumption, depending on the process, cleanroom classification and operating conditions. 

That single number is why so many pharma companies now evaluate their turnkey construction firms on energy performance, not just square footage and timelines. So let’s examine it. What’s driving these costs? What does a turnkey partner actually do? And how do you choose one that builds in efficiency from day one, introducing it through later-stage modifications?

What’s Driving Modern Pharma Facility Energy Costs

What's Driving Modern Pharma Facility Energy Costs

Pharma plants are significantly more energy-intensive than most buildings. As a consulting-specifying engineer summarised in 2019, “The average energy use intensity of a typical commercial office built after 2000 is roughly 81.4 kBtu per square foot per year, while the average pharmaceutical plant is around 1,210 kBtu per square foot per year.”That gap is from cleanroom conditioning, process equipment, and utility generation operating for extended periods. These figures represent a broad US comparison, and actual energy performance can vary substantially by process, climate, classification and operating schedule. 

This is why HVAC takes so much of that load. The fans, filters, chillers, and dehumidifiers that do that job may operate continuously or for extended periods, depending on the area and manufacturing schedule, and cleanrooms need controlled ventilation to maintain specified environmental conditions and airborne-particle limits. Cleanroom energy benchmarking research has found that HVAC use in cleanrooms accounts for between 36% and 67% of the total facility energy, depending on the process. When a construction partner discusses modern pharma facility energy costs, the conversation will usually begin with air-handling design. 

The good news is that high energy use is not entirely fixed as an unavoidable cost of doing business. For example, in a case where Roche and Genentech reduced air change rates in an existing facility using a multidisciplinary, risk-based assessment, the project reduced airflow volume and resulted in a 14% reduction in energy use and greenhouse-gas emissions, with annual savings of more than $678,000. Such results can be supported by making the right design choices at the construction stage while also reviewing existing systems through risk assessment, monitoring, change control and requalification where required, which is precisely where experienced turnkey partners can add value. 

What Turnkey Construction Firms Actually Do

Turnkey companies may take a pharma project from concept development to a qualified, operating facility. In practice, that means five phases, generally:

  1. Engineering design – process flow, cleanroom classification, HVAC, and utility layout specific to dosage form.
  2. Procurement – purchase of manufacturing equipment, machinery, and building materials.
  3. Construction and installation – civil, structural, mechanical, electrical, and plumbing work on site
  4. Commissioning, qualification, and validation (CQV) – confirming that systems function as intended, providing documented evidence that facilities, utilities and equipment meet approved requirements, and supporting applicable process-validation activities.
  5. Project management – keeping the budget, schedule, and all moving contractors on track.

FDA guidance describes process validation as a lifecycle activity that establishes scientific evidence that a manufacturing process can consistently deliver quality products. Qualification of facilities, utilities and equipment forms part of that lifecycle, but responsibility for product quality and the validated state remains with the manufacturer and its Quality Unit. 

The attraction is simple. The owner gets a single point of accountability for pharmaceutical facility design and construction from concept to handover rather than dealing with a design firm, builder, equipment vendor, and validation consultant separately.

How to Choose the Right Partner

How to Choose the Right Partner

Not all construction companies offering “turnkey” delivery demonstrate the same capability in energy-performance design. This is what really distinguishes the ones that do from the ones that cannot demonstrate it through documented project evidence.

Track record across dosage forms

Biotech, sterile injectables, oral solids, and API plants have different cleanroom classifications, process risks, containment strategies and HVAC requirements. A company that has only built oral solid dosage plants may not have the airflow modelling experience needed for a sterile injectable facility. Request for project references related to your specific dosage form and scale.

ISO 14644-1 classifies cleanrooms by airborne-particle concentration, while the wider contamination-control, process and regulatory requirements determine how the facility and its HVAC systems should be designed and operated.

In-house engineering, not just subcontracted labor

Companies that have in-house HVAC, process, and MEP (mechanical, electrical, and plumbing) engineering usually catch energy waste earlier, at design, when it’s cheapest to fix. Concrete is expensive to change once it is poured, and an oversized air handling unit is no exception.

Sustainability built into design, not added later

Ask how the firm deals with validated airflow-setback strategies in suitable areas, variable-speed drives on fans and risk-based air-change rates instead of relying on worst-case assumptions. This is consistent with the WHO’s technical guidance on HVAC in non-sterile pharmaceutical manufacturing, which recommends a comprehensive science- and risk-based approach across the HVAC lifecycle, beginning at the initial design stage. Oversized systems can increase capital and operating energy without necessarily improving contamination control. 

A real compliance and validation history

An energy-efficient design is of limited value if it does not support applicable regulatory and quality requirements. Look for companies with proven experience across cGMP-focused and regulated-market projects, as well as relevant organisational ISO certifications, established quality systems and documented CQV procedures.

FDA does not generally certify pharmaceutical engineering companies, and GMP should not be presented as a personal certification held by an engineering team. Organisational certifications such as ISO 9001, ISO 14001 and ISO 45001 relate respectively to quality, environmental, and occupational-health-and-safety management systems. Pharma Access states that it holds these three management-system certifications.

The Role of AI for Predictive Maintenance in Pharma Plants

Building is only the beginning. Once a facility is up and running, equipment reliability is the next lever on both energy usage and product quality. A worn pump or drifting compressor is not merely a downtime risk. destabilise environmental or process control and contribute to a deviation.

This is where AI for predictive maintenance in pharma plants has begun to improve maintenance planning. According to industrial predictive-maintenance research, combining AI or analytical models with IoT-enabled sensor data can help teams identify developing equipment faults before failure, supporting planned maintenance and improved operational reliability. The benefits depend on sensor coverage, data quality, equipment criticality, system integration and the engineering and financial suitability of the application. 

So the bottom line for a facility owner is to ask your construction partner if the building is being designed for sensor infrastructure and appropriate BMS, EMS, equipment-control, historian and maintenance-system integration from day one. Retrofitting monitoring hardware into finished cleanrooms is a far more disruptive process than wiring it in during construction. Network-based access to real-time manufacturing-system data can also support maintenance and troubleshooting, subject to appropriate access control, cybersecurity and GxP data-governance requirements. 

Where Engineering Consulting Services Fit In

Not every project requires a full turnkey contract. Some owners engage engineering consulting services for a more limited scope, such as HVAC optimisation, cleanroom layout review, or a feasibility study, before committing to a full build. This path is well-suited for brownfield expansions or facilities that require only targeted upgrades rather than ground-up construction.

The price is coordinated. The owner would still have to separately manage the builder, equipment vendors, and the validation team with only consulting support. A turnkey model rolls all of that under one contract, which tends to reduce the number of handoffs where miscommunication (and cost overruns) creep in.

A Look at How This Plays Out in Practice

A Look at How This Plays Out in Practice

Pharma Access is a Mumbai-based pharmaceutical engineering and turnkey construction company that has been working on biotech, sterile manufacturing, oral solid dosage and API projects for more than 25 years. Its service offering covers the entire chain: engineering design, procurement, construction and installation, CQV and project management, all under one roof. The firm has also developed a Modular Mobile Facility approach, designed to support controlled off-site fabrication, parallel execution, faster site installation and scalable facility delivery compared with fully site-built approaches, where suitable for the project. Pharma Access currently states that it has completed more than 120 projects for over 100 clients across 18+ countries.

The point is there is more than one firm to choose from. It’s the delivery capability that counts, not the marketing. Compare Pharma Access with other qualified project partners and ask the same questions. Who does the HVAC modelling? Who supports CQV delivery, and how are responsibilities divided between the partner, owner and Quality Unit? And what about the design plan for energy use during the next twenty years, not just at initial project handover?

Questions to Ask Before You Sign

  • Do you have energy modelling data from a previous similar project?
  • How do you determine and justify airflow quantities and air-change rates for our particular process, room classification and contamination-control requirements?
  • Does the base design incorporate predictive maintenance infrastructure, or is it added later at extra cost?
  • What organisational ISO certifications, regulated-market project experience and quality systems do you have, and can we see supporting evidence?
  • Who supports CQV activities? Is it an internal team or outsourced?

Next steps: Choose two or three firms to be your finalists, ask for references on your dosage form, and compare their answers to the side-by-side questions above. Usually, the difference between a good answer and a vague one tells you everything you need to know.

Frequently Asked Questions

What makes a construction firm “turnkey” in pharma projects? 

A turnkey company manages an integrated project scope that may include engineering design and procurement through construction, CQV support and project management under one contract. The owner has one primary accountable project partner, instead of coordinating separate vendors for each phase, although the precise responsibilities must be defined in the contract.

Why do pharmaceutical facilities use so much more energy than office buildings? 

Cleanrooms require controlled volumes of filtered air, defined temperature and humidity conditions, and pressure differentials between selected rooms to control contamination or provide containment. This keeps HVAC systems running for extended periods and, in some critical areas, continuously, which is why pharma plants use far more energy per square foot than standard commercial buildings.

How does AI-based predictive maintenance actually save money in pharma plants? 

Sensors monitor the condition of equipment in real time and signal the first signs of wear or abnormal performance. This allows teams to plan repairs before a functional failure occurs, helping to reduce the risk of unplanned downtime, emergency repairs, process disruption and associated deviations. The value depends on equipment criticality, sensor selection, data quality and the maturity of the maintenance system.

Should I hire a turnkey firm or separate engineering consulting services? 

It depends on the scope. For a full new build, a turnkey contract may be more suitable when the owner wants integrated coordination across multiple disciplines. Standalone engineering consulting services often work well for a targeted upgrade, such as an HVAC retrofit, or when the owner has the internal capability to manage the remaining contractors and vendors.

How long does a turnkey pharmaceutical facility project typically take? 

For example, a targeted upgrade may take several months, whereas a large greenfield biotech plant could take several years. These timelines can vary considerably depending on facility size, dosage form, regulatory region, site readiness, long-lead equipment, owner approvals and CQV scope. In some cases, selected design, fabrication and installation activities can be reduced with modular construction procedures.

Posted on

Turnkey Pharmaceutical Plant in Saudi Arabia: 10 Critical Stages

Turnkey Pharmaceutical Plant in Saudi Arabia: 10 Critical Stages

Turnkey Pharmaceutical Plant in Saudi Arabia projects are becoming increasingly important as Saudi Arabia develops one of the most ambitious pharmaceutical industries in the Middle East. The Kingdom’s pharmaceutical market reached a value of about USD 11.6 billion in 2024. Around 30% of pharmaceutical products are manufactured locally, according to official Saudi investment material. That figure has a clear target under Vision 2030: to localise 40% of the market value in the pharmaceutical industry through domestic manufacturing investment, industrial zone development, and technology transfer partnerships.

Pharma companies looking to enter or expand in the Saudi market often find themselves asking one question early on: what does it actually mean to set up a compliant, production-ready plant? For most projects, the answer is a Pharma Turnkey Solutions in Saudi Arabia, an integrated project-delivery model that covers all stages from initial design to qualified and documented handover.

Here’s a look at what’s in that model, why it matters in the Saudi context, and what investors and manufacturers need to know before they begin the project.

1. Why Saudi Arabia Demands a Turnkey Approach

Building a pharmaceutical facility is not the same as building a typical industrial warehouse.

 The Saudi Food and Drug Authority (SFDA) GMP Guidelines aligned with internationally recognised GMP principles, including applicable PIC/S guidance.
All room classifications, airflow patterns, surface finishes and drainage points must be designed according to the dosage form, process and contamination-control requirements. The SFDA conducts site inspections, with the duration depending on the facility scope and complexity, and can issue non-compliance findings that can delay licensing, GMP certification or related regulatory activities. 

With a turnkey approach, one engineering partner handles the full scope: design, procurement, construction, installation, commissioning, and qualification and validation (CQV). That one point of responsibility reduces the gaps in coordination that happen when you have more than one contractor working separately. When all disciplines report to one team, compliance is designed from day one, not corrected at the end.

Vision 2030 aims to localise 40% of the market value in the pharmaceutical industry. Companies that can quickly and compliantly commission facilities will be best positioned to capture that growth.

2. Pre-Project Feasibility and Site Assessment

Every turnkey pharmaceutical plant in Saudi Arabia starts a long way before the first brick is laid.

The feasibility phase includes the following:

  1. Site assessment – evaluating availability of land, classification of industrial zone, proximity to utilities, site-access requirements and capacity of local infrastructure
  2. Regulatory mapping – what SFDA licensing and registration pathways https://www.sfda.gov.sa/en/news/88414 are relevant for the product type (e.g., oral solid dosage, sterile injectables, biologics, API, etc.)
  3. Production capacity planning – determining batch sizes, room requirements, equipment capacities and throughput demands from market forecasts
  4. Budget framework — preparing a capital expenditure estimate prior to detailed design

A typical greenfield pharmaceutical facility, from concept approval to first product batch, may take 3 to 5 years. This may include design (6-12 months), construction (12-24 months), and CQV (12-18 months) although activities may overlap and timelines depend on project complexity, equipment lead times and regulatory requirements.Modular construction approaches can reduce selected project phases when design standardisation, site readiness, approvals and logistics are properly coordinated.

A detailed upfront feasibility assessment helps keep the timeline on track and avoids costly redesigns down the line.

3. Engineering Design — the Foundation of GMP Compliance

The principle is straightforward.
Good manufacturing practice is not something you tick off at the end of the day. It is a core design consideration. Every choice in the engineering phase, from room pressure differentials to floor drain placement, either helps or hurts the regulatory outcome.

A full pharma engineering solution package in Saudi Arabia comprises the following:

  • Process design — setting up production workflows, room adjacencies, and personnel, material, product and waste-flow paths to prevent cross-contamination
  • Architectural and structural design – selection of wall systems, types of ceilings, floor coatings, and door specifications to meet cleanroom requirements;
  • HVAC design — engineering heating, ventilation, and air conditioning systems to maintain the required cleanroom grades or controlled environmental conditions,  temperature, humidity, and differential pressure
  • MEP systems – mechanical, electrical, and plumbing design, including compressed air, nitrogen, clean steam, and Water for Injection where required by the process.
  • Automation and IT – Building Management Systems (BMS), Environmental Monitoring Systems (EMS), and SCADA Integration
  • ELV systems – access control, CCTV, and fire and life safety systems
  • Quality control laboratory – a dedicated, appropriately controlled QC laboratory for in-process testing and batch release

Today, pharmaceutical engineering solutions utilise simulation-based tools before the construction phase. GMP compliance is designed into the project rather than retrofitted into the project later in the project lifecycle, with more sophisticated simulation tools to model HVAC performance, room classification, and material flow paths by engineering teams.

Digital-twin technology is also being evaluated in pharmaceutical manufacturing projects. Turnkey companies may develop these simulation models as part of the design package, giving the client a virtual facility to stress-test before a single beam is put up.

4. Procurement and Supply Chain Management

Pharmaceutical process equipment is not a ready-to-use item. The tablet press machines, isolators, autoclaves, WFI generation systems, and cleanroom air handling units all come from specialised suppliers with different technical capabilities, documentation standards and delivery timelines. Mistakes in procurement, such as purchasing equipment that does not meet the approved User Requirement Specification or cannot support documented qualification, can cost months of delay.

A turnkey project covers procurement for the following:

  • Manufacturing process equipment (granulators, coaters, fillers, capsule filling machines, lyophilisers, etc., depending on the dosage form)
  • Utility equipment (water purification systems, clean steam generators, compressed gas systems)
  • Cleanroom panels, doors, and pass-through systems
  • HVAC air handling units and filtration
  • Analytical equipment and laboratory instruments
  • Automation Equipment (PLCs, SCADA, DCS)

In turnkey pharmaceutical projects, the procurement process favours the use of technically evaluated and qualified suppliers and equipment with a history of success in the pharmaceutical sector and documentation that supports GMP qualification.

Procurement for a turnkey pharmaceutical plant in Saudi Arabia also involves customs documentation, clearance through the Zakat, Tax and Customs Authority (ZATCA), and liaison with local freight agents. Part of the scope is an experienced turnkey partner who handles all of this in accordance with the agreed procurement and logistics responsibilities. 

5. Construction and Installation

Construction and Installation

GMP facility construction is unlike your typical civil construction in several ways. 1. Materials must be traceable. Cleanroom panels need to be installed in a controlled sequence. HVAC ductwork must be protected from contamination and internally clean before installation. Any change from the approved design must be handled through a formal change-control process.

The construction phase consists of:

  • Civil, Structural & Foundation Works
  • Installation of cleanroom wall, ceiling, and floor
  • HVAC ductwork fabrication and installation
  • Piping and plumbing of process and utility services
  • Installation of lighting and electricity
  • Fire suppression and life safety systems
  • Site infrastructure and landscaping

During the construction phase, strict quality assurance practices are followed to ensure the integrity of the cleanroom and the traceability of the materials. The construction teams also work closely with engineering and validation units to maintain quality checkpoints such as material inspections, installation checks, duct-cleanliness inspections, pressure testing and punch-point closure.

In Saudi Arabia, construction must also adhere to applicable Saudi Building Code requirements, SASO standards, and coordinate with municipal authorities for permits and inspections.

6. Pharma Effluent Treatment and Waste Management

“Here is an area that investors sometimes underestimate until it becomes a project or environmental-compliance issue.

One of the most important requirements for pharmaceutical factories in the Kingdom of Saudi Arabia is an approved wastewater-management strategy appropriate to the effluent characteristics and site conditions. Active pharmaceutical ingredients (APIs), solvents, and cleaning agents present in the wastewater must be treated to acceptable concentrations before discharge to the drainage system, in accordance with the applicable permit and discharge limits.

Depending on the industrial zone, available infrastructure and wastewater characteristics, this may involve on-site treatment, pretreatment before discharge or connection to an authorised central treatment system.

A typical pharmaceutical effluent-treatment system may include the following:

  • Pre-treatment (pH neutralization, solids removal)
  • Biological treatment (activated sludge, MBBR, or MBR technology)
  • Tertiary treatment (filtration, disinfection)
  • Re-use options for treated water (cooling systems, irrigation, cleaning)

Advanced membrane bioreactor (MBR) technology provides high-quality treated water without chemicals and produces clear, low-suspension output that is suitable for reuse in cleaning, cooling, and landscaping applications. These systems are ideal for new pharma plants or upgrades to existing facilities in Saudi Arabia and the UAE.

A properly designed system for treating the effluent is necessary where required by the environmental permit and discharge conditions. It is not a universal standalone condition of the SFDA manufacturing licence, although the facility must comply with all applicable environmental and industrial-zone requirements.

7. Commissioning, Qualification, and Validation (CQV)

Commissioning, Qualification, and Validation (CQV)

This is the point at which documented evidence is generated to support the facility’s GMP readiness. CQV is a systematic process to demonstrate that all systems, rooms, and equipment operate as required, within the limits necessary for drug production.

Let’s break it down into three stages:

  • Commissioning – Ensuring all systems are installed properly and functioning as specified by the engineering team.
  • Qualification – the four-step GMP check sequence:
  • Design Qualification (DQ): confirms that the design fulfills approved User Requirement Specification and applicable GMP requirements
  • IQ (Installation Qualification): Equipment is installed and configured according to approved drawings, specifications and manufacturer requirements
  • Operational Qualification (OQ): confirms equipment functions properly across defined operating ranges and control functions.
  • Performance Qualification (PQ): confirms that the equipment can consistently deliver results under normal manufacturing conditions
  • Validation – Process validation, cleaning validation, and computer system validation (CSV) of any software-controlled equipment or systems.

In the pharmaceutical industry, turnkey solutions are typically handled via EPC (Engineering, Procurement, Construction) or EPCM contracts.


These are different delivery models. Under EPCM, the provider manages engineering, procurement and construction activities on behalf of the owner rather than acting as the construction contractor.
In the EPC turnkey model, the provider assumes the responsibilities and risks allocated in the contract, and GMP-compliant validation support may form part of the turnkey handover, depending on the agreed scope. In technical commissioning, a clear distinction is made between the Factory Acceptance Test (FAT) at the manufacturer’s plant and the Site Acceptance Test (SAT) at the final location. FAT and SAT records may support qualification but do not automatically replace IQ or OQ unless this approach is justified and documented. 

The documentation package produced by the CQV process is what the SFDA inspectors review during a GMP inspection. It supports the regulatory readiness of the facility.

8. Regulatory Readiness and SFDA Licence Preparation

Setting up a turnkey pharmaceutical plant in Saudi Arabia requires working with the SFDA at every step, not just at the end.

Manufacturers in Saudi Arabia must be licensed by the SFDA. Facilities are regularly audited for GMPs and inspected by regulatory agencies. Domestic and foreign manufacturers are required to comply with the SFDA’s GMP Guidelines, which are aligned with internationally recognised GMP principles and applicable PIC/S guidance. Depending on the manufacturer’s legal structure and registration pathway, a Saudi entity, authorised agent or local representative may be required for specific regulatory activities.

The SFDA inspection team may visit the site to conduct a comprehensive GMP evaluation of relevant production lines, utilities, quality systems and supporting operations. Manufacturing sites can expect a tough three- to five-day assessment.

A turnkey partner with experience in the MENA region can prepare the regulatory documentation of the facility in parallel with the construction so that GMP dossiers are ready when the building is ready.

9. Project Management Across the Full Lifecycle

Project Management Across the Full Lifecycle

A turnkey pharmaceutical plant is not a construction contract. It is a programme management exercise that spans years and involves dozens of specialist disciplines.

Pharma turnkey solutions include dedicated project management covering the following:

  • Master programme planning and schedule control
  • Cost management and change control
  • Risk tracking and mitigation planning
  • Vendor and subcontractor management
  • Document control and regulatory correspondence
  • Commissioning and handover coordination

One central team manages architecture, mechanical systems, and specific process workflows under a single point of responsibility for the entire build. This centralised structure minimises technical errors and prevents costly redesign loops. Engineering teams communicate directly with equipment manufacturers to ensure technical coordination across equipment, utilities and facility interfaces.

Pharma Access, with 25+ years of experience and more than 120 projects across 18+ countries, including projects in Saudi Arabia and other MENA markets, uses this integrated project-management model to support schedule, cost and execution control across complex pharmaceutical projects.

10. What the Turnkey Handover Actually Looks Like

At the end of a well-executed turnkey project, the client receives much more than a set of building keys.

A full turnkey package for a pharmaceutical plant in Saudi Arabia comprises:

  • A fully commissioned facility with systems qualified within the agreed CQV scope and supporting documentation.
  • Complete set of as-built engineering drawings.
  • Maintenance schedules, spare-parts lists and equipment manuals.
  • Facility operating SOPs, where included in the agreed project scope.
  • Qualification and validation protocols and reports according to the agreed project responsibilities.
  • Staff training records for the equipment, utilities and systems covered by the provider.
  • A GMP-compliant regulatory-readiness documentation package.

Thereafter, the client can complete the remaining SFDA manufacturing-licence, GMP-certification, product-registration, technology-transfer and operational-readiness activities. Commercial manufacturing can begin after the required approvals, quality systems, validated processes and product authorisations are in place. 

Frequently Asked Questions

What is a turnkey pharmaceutical plant in Saudi Arabia? 

A turnkey pharmaceutical plant in Saudi Arabia is a contract for the complete facility setup, where one company is responsible for the design, procurement, construction, installation, and validation. The client receives a facility ready for SFDA GMP inspection and commercial production at handover, without having to deal with multiple independent contractors.

How long does it take to set up a pharmaceutical manufacturing plant in Saudi Arabia? 

In a greenfield pharmaceutical plant, it usually takes three to five years from concept to the first batch of production. These include 6-12 months of design, 12-24 months of construction, and 12-18 months of commissioning, qualification, and validation. Although these phases may overlap and the schedule depends on the project scope.

What does SFDA require for pharmaceutical manufacturing approval in Saudi Arabia? 

All sites for the manufacture of pharmaceuticals require a GMP licence from the SFDA. Manufacturers are required to adhere to the SFDA GMP Guidelines based on the WHO and PIC/S standards, submit a Common Technical Document (CTD) dossier for each product, and pass a site inspection, including facility design, equipment qualification, documentation systems, and review of the live production line.

Do pharmaceutical plants in Saudi Arabia need effluent treatment systems? 

Yes. Pharmaceutical manufacturers must have an approved wastewater-management approach that meets the applicable environmental, industrial-zone and discharge requirements.The facility setup may require on-site treatment, pretreatment before discharge or connection to an authorised central treatment system, depending on the wastewater characteristics and site infrastructure.In the Kingdom, membrane bioreactor technology is one of several treatment technologies that may be considered, depending on the effluent composition, treatment objectives and permitted discharge or reuse conditions.

How does pharma engineering with simulation tools improve a turnkey project?

The project team can model HVAC performance, cleanroom pressure differentials, and material flow paths before construction by using simulation-based engineering. This allows design problems to be found early, when they are easier and less costly to fix, rather than during construction or CQV, when they are expensive and time-consuming to correct.Simulation-based engineering forms part of Pharma Access’s approach to pharmaceutical-facility design and integrated project delivery.

Posted on

Benefits of Pharma Turnkey Consultancy Services for Your Next Facility Project

Benefits of Pharma Turnkey Consultancy Services Solutions

It is no small feat to build a pharmaceutical manufacturing facility. You need architects who understand GMP facility design and cleanroom classifications , you need engineers who know HVAC systems for controlled and sterile manufacturing environments, and a team that can support commissioning and qualification without fragmented communication between multiple project stakeholders.
This is where pharma turnkey consultancy services come in. Work with one partner who takes care of the design, the build, and the handover within an agreed project scope, rather than working with ten different vendors, hoping they talk to each other.

That is why this approach has become increasingly relevant for pharmaceutical facility projects. Here is what it looks like on a real project.

What This Type of Consultancy Actually Covers

What This Type of Consultancy Actually Covers

The turnkey consultant doesn’t just draw plans and then go away. The scope is usually everything from that first concept sketch to the day you turn the key and prepare the facility for production. That usually involves:

  • Mechanical, Electrical, Plumbing, Cleanroom Layout (Pharmaceutical Facility Design)
  • Procurement of machinery and process equipment
  • Construction and installation
  • Commissioning, Qualification and Validation (CQV)
  • Project management from start to finish

Because one team has all these pieces, you have fewer gaps between design intent and what’s actually built. If the cleanroom drawing does not match what the HVAC contractor installs, that mismatch is caught early rather than during qualification or a regulatory inspection.

Why Pharmaceutical Companies Turn to Turnkey Consultants

One Team, One Contract, One Point of Contact

Divide a facility project into a design firm, a construction contractor, and a validation consultant, and you have the person who has to tie them all together. All change orders may require multiple approvals. Responsibility for every delay can also become unclear. In a turnkey model, one contract covers the whole scope, and one team is responsible for the outcome. If an issue arises, you know exactly who to call.

Shorter Build Times

Shorter Build Times

When design, procurement, and construction are all under one roof, they can be better controlled. The construction crew doesn’t wait weeks to get an answer to a question from a design firm because the engineers sit down the hall. One team follows both timelines to the same master schedule, allowing equipment procurement to begin while civil work is still underway. That overlap could shorten the overall project timeline by several months on a complex facility project.

Regulatory Know-How From the Start

Regulatory Know-How From the Start

Preparing a facility for FDA assessment and inspection is not something you tack on at the end. The Current Good Manufacturing Practice (CGMP) regulations in 21 CFR Parts 210 and 211 outline the minimum requirements for the methods, facilities, and controls used in the manufacture of a drug product.
The inspectors look at the physical building as well as the paperwork and operational systems  to ensure compliance with these rules. The FDA’s review of new and generic drug marketing applications includes an assessment as to whether the manufacturer is in compliance with CGMP. The agency’s assessors determine if the firm has the facilities, equipment, and ability to manufacture the drug it plans to market. Good pharmaceutical engineering consultants integrate cleanroom classifications, airflow design, and documentation practices into the layout from day one, so the building supports an inspection instead of fighting it. In addition to FDA rules, many projects must also comply with WHO good manufacturing practice guidelines, which establish quality standards for production and quality control and require that personnel, premises, and materials be suitable for the production of pharmaceuticals and biologicals, including vaccines.
For API manufacturing projects, ICH Q7 may also be relevant, depending on the product, project location and intended regulatory markets. 

The turnkey consultant can support GMP-aligned facility design, qualification and inspection readiness, but the pharmaceutical manufacturer remains responsible for its quality system, regulatory submissions, process validation and ongoing GMP operations.

Budget Certainty

Scope changes are often the cause of facility build cost overruns that no one caught in time. A turnkey partner may quote the defined project scope upfront – equipment, labour, validation, etc. – so you don’t get surprise change orders three months into construction. Of course, you still have to read the contract in detail, but the fact that there is one accountable scope makes it a lot easier to track spend against a fixed baseline. Final project costs can still be affected by client-requested changes, unforeseen site conditions, equipment changes, regulatory requirements and other contract exclusions. 

Access to Specialized Facility Design Skills

Sterile injectable lines, biotech suites, and oral solid dosage plants all have different HVAC pressure cascades, material flows, and equipment layouts. Experienced pharmaceutical facility consultants have engineers who have already solved these problems on other projects. That kind of pattern recognition, the ability to know which layout errors lead to validation headaches down the road, is hard to develop in-house unless facility construction is a regular part of your business.

What Sets the Top Pharma Consulting Firms Apart

Not every company that calls itself a turnkey provider actually does end-to-end work. Here’s what to watch for:

  1. Experience with comparable dosage forms: A company that already has oral solid-dose plants may not have the same experience levels in sterile injectables or cell and gene therapy suites. Ask for references of projects that are similar to your product type.
  2. Drawings outsourced, in-house engineering, not only: Companies with their own mechanical, electrical, and process design teams can move faster and catch conflicts before construction starts.
  3. Proper CQV process: Commissioning, qualification, and validation should be planned in parallel with design and not as a final step.
  4. Certifications to support their cases: A company with documented internal processes may hold certifications such as ISO 9001 for quality, ISO 14001 for the environment, and ISO 45001 for health and safety. These certifications should be evaluated alongside relevant project experience, engineering capabilities and client references. 
  5. A project management structure you can feel: You want named contacts, not a revolving door of subcontractors.

One company that has built on this model is Mumbai-based engineering and construction firm Pharma Access. With more than 25 years of experience , it has worked on pharma and biotech facility projects in more than 18+ countries, including biotech, sterile manufacturing, oral solid dosage, oral liquid dosage, and API facilities. 120+ projects for more than 100 clients.It is ISO 9001, ISO 14001, and ISO 45001-certified. The point is not that one firm fits all projects. It is the sort of background that is worth checking out before you sign anything.

How Pharma Turnkey Consultants Handle a Project, Step by Step

How Pharma Turnkey Consultants Handle a Project, Step by Step

A typical turnkey engagement typically follows a five-step process:

  1. Feasibility and design concept: The consultant will review your product mix, capacity requirements, and site options and develop an early layout and budget range.
  2. Detailed engineering: Mechanical, electrical, plumbing, and process drawings are finalised, as well as cleanroom classifications and equipment specifications.
  3. Procurement and construction: Equipment was ordered, civil work started, and installation according to the coordinated schedule.
  4. Commissioning, qualification & validation: Facilities, utilities and equipment are tested and qualified for their intended use.Documentation is compiled. The facility is prepared for regulatory inspection.
    Process validation activities are completed by, or in coordination with, the manufacturer’s quality and production teams. 
  5. Handover and support: Operators are trained, and the facility is handed over to your production team.
  6. This is an important order: One of the most common reasons projects go over budget is that construction begins before the design is sufficiently developed.

Common Mistakes to Avoid When Hiring a Turnkey Partner

  • Going by price only: The low bidder may not include the same level of detailed engineering, which comes out later as change orders.
  • Not checking dosage-form experience: A company that’s strong in tablets may struggle in sterile rooms.
  • Skipping CQV planning until construction is done: CQV must be in on the design discussion from the beginning.
  • Not reviewing earlier projects: Photos and case studies do not tell you how a facility actually works.

A short list like this can save you months of rework once you get into the contract negotiations with a pharma turnkey consultancy firm.

Wrapping Up

Pharma turnkey consultancy services are designed to take the headache of coordinating the construction of a compliant, working facility from scratch. You have one team that is responsible for the agreed design, construction and CQV scope, which can mean better-controlled timelines, greater budget visibility and fewer late-stage surprises before inspection. That combination of engineering depth and hands-on project delivery can look like companies such as Pharma Access. The questions to ask are the same if you go with a big firm or a smaller specialist. What have they built before? Who owns the schedule, and how early does validation planning start?

Frequently Asked Questions

What is the difference between a turnkey consultant and a regular engineering firm? 

A design-only engineering company only designs, so you have to hire separate contractors for construction and validation. A turnkey consultant takes design, procurement, construction, and CQV and bundles them into a single contract, with one team responsible for agreed facility-project scope.

How long does a typical pharma turnkey project take? 

Timelines depend on the type and size of facility, but a small to mid-size  oral solid dosage plant may take approximately  18 to 24 months from design to handover. Sterile or biotech facilities usually take longer due to additional cleanroom and validation requirements.These timelines are indicative and can vary depending on project scope, site conditions, regulatory requirements, approval timelines and equipment lead times. 

Do turnkey consultants handle FDA and WHO compliance documentation? 

Most experienced companies includeGMP and qualification requirements design, such as cleanroom classification, airflow studies, and facility, utility and equipment qualification documentation, to support compliance with FDA CGMP requirements as well as WHO good manufacturing practice guidance. However, the manufacturer remains responsible for its pharmaceutical quality system, batch documentation, process validation, regulatory submissions and ongoing GMP compliance. 

Is a turnkey model more expensive than hiring separate contractors? 

Not necessarily. It might seem that the initial quote is higher, but one accountable contract tends to mitigate the change orders and delays that drive up costs with multiple vendors.

Can a turnkey consultant work on an existing facility, not just a new build? 

Yup. Many companies perform brownfield expansions and upgrades within existing facilities, applying the same design-build-validate approach to adding capacity or new product lines without shutting down existing operations.

Posted on

Top Pharma Turnkey Company in Andheri West, Mumbai

Top Pharma Turnkey Company in Andheri West Mumbai

Mumbai’s pharmaceutical sector is one of the most active in the country. And within Mumbai, Andheri West has quietly become a preferred address for pharma consultancy and engineering firms. If you are planning to set up or expand a pharmaceutical facility, finding the right pharma turnkey company in Andheri West can save you months of coordination and a great deal of money.

This post explains what pharma turnkey projects services actually cover, why Andheri West works as a base for these companies, and what you should check before signing with any firm.

What Does a Pharma Turnkey Company Actually Do?

A pharma turnkey company takes responsibility for a project from start to finish. The client hands over the requirements, and the firm manages everything: engineering design, procurement, civil construction, equipment installation, and final validation.

Let’s break it down. A standard turnkey scope for a pharmaceutical facility covers:

  • Engineering design: Process flow development, cleanroom classification, HVAC system design, MEP (mechanical, electrical, plumbing), piping, waste management, and automation.
  • Procurement and supply: Sourcing process equipment and machinery that meet cGMP standards.
  • Construction and installation: Civil, structural, and architectural work along with modular cleanroom build-outs.
  • Commissioning, Qualification, and Validation (CQV): Testing and documenting that every system performs as intended before a drug product is manufactured.
  • Project management: Scheduling, budgeting, vendor coordination, and regulatory documentation.

When a firm offers all of these under one roof, the client avoids coordination gaps between multiple contractors when challenges arise during project execution. The turnkey model puts accountability in one place.

Why Andheri West Works for Pharma Turnkey Firms

Andheri West is not a random choice. Here is why the location makes practical sense for a pharma turnkey company in Mumbai.

  • Connectivity to pharma manufacturing clusters: Maharashtra’s major pharma production zones, including those in Navi Mumbai, Taloja, Ambernath, and Badlapur, fall within a 45 to 90-minute drive of Andheri West. Project teams can reach sites without losing half a day to commute.
  • Access to talent: Mumbai has a large pool of pharmaceutical engineers, cGMP compliance professionals, and project managers. Andheri West’s position near the Western Express Highway and its metro connectivity makes it easier for firms to attract and retain qualified staff.
  • Airport proximity: Chhatrapati Shivaji Maharaj International Airport sits adjacent to Andheri. For firms running projects in the MENA region, Southeast Asia, or other international markets, this matters every week. Engineers and project leads can fly out and return without losing two days to travel logistics.
  • Vendor and supplier ecosystem: Andheri and its neighbouring areas in western Mumbai host a large number of industrial equipment suppliers and specialised contractors. A turnkey firm operating from here can hold supplier meetings, inspect samples, and finalise contracts without extensive travel.
  • Regulatory access: Key government and regulatory offices, including those linked to the Central Drugs Standard Control Organisation (CDSCO), are reachable from Mumbai. Being in the city puts a firm closer to the regulatory conversation.

What Services Should a Good Pharma Turnkey Company Offer?

Not every firm that calls itself a pharma turnkey company delivers the same scope. Here is what a genuinely full-service firm should cover.

Engineering Design for Diverse Dosage Forms

Engineering Design for Diverse Dosage Forms

The engineering work should go beyond generic cleanroom drawings. A capable firm should design facilities for:

  • Oral solid dosage (OSD): tablets, capsules, sachets, effervescent and extended-release formats
  • Sterile manufacturing: injectables including LVP, SVP, vials, ampoules, pre-filled syringes, and lyophilised products
  • Oral liquid dosage: syrups, suspensions, emulsions
  • Biotechnology: monoclonal antibodies, vaccines, cell and gene therapy, peptides, insulin
  • Active pharmaceutical ingredients (API): covering biological routes, chemical routes, oncology, and cephalosporins

Each dosage form has a different contamination risk profile, and the facility design, HVAC classification, and pressure differentials must match those risks. A firm that has actually built different types of facilities brings a different calibre of thinking to the design table.

Regulatory Compliance Built into the Design

GMP compliance is not something you bolt on at the end. It needs to be baked into every design decision: room finishes, air change rates, material flow, personnel flow, drain placement. A firm that builds facilities for GMP-regulated environments should be familiar with WHO GMP guidelines, US FDA cGMP requirements (21 CFR Parts 210 and 211), EU GMP Guidelines, including Annex 1 where applicable, and the Revised Schedule M requirements under the Drugs and Cosmetics Rules.

The Drugs and Cosmetics Act, 1940, along with the Drugs and Cosmetics Rules and subsequent amendments, governs pharmaceutical manufacturing in India. The Revised Schedule M prescribes the Good Manufacturing Practices (GMP) requirements that pharmaceutical manufacturers are expected to follow. Any pharma turnkey firm working in India should have a thorough understanding of these regulatory requirements.

Commissioning, Qualification, and Validation (CQV)

Commissioning, Qualification, and Validation (CQV)

CQV is where a lot of turnkey projects go soft. Design and construction can look fine on paper, but if the firm cannot qualify the HVAC system, validate the water system, or complete the equipment qualification documentation to a regulatory standard, the client ends up hiring another consultant to fix it. A proper pharma turnkey company in Andheri West should have in-house CQV capability, not just engineering teams.

Modular and Prefabricated Facility Options

Conventional construction takes time. Modular construction, where sections of the facility are prefabricated off-site and assembled on location, cuts project timelines and reduces on-site risk. Some firms have developed proprietary modular facility concepts that allow faster installation with consistent quality.

Project Management Across Geographies

A pharma turnkey firm with a strong track record will have completed projects outside India. This matters because it signals that the firm can manage international vendor relationships, deal with customs and logistics, and coordinate multilingual teams on site.

Critical Utility Systems

In addition to process equipment and facility construction, a pharmaceutical turnkey project should include the engineering and integration of critical clean utility systems, including Purified Water (PW), Water for Injection (WFI), Clean Steam, Compressed Air, HVAC, Building Management Systems (BMS), and Electrical & Utility Distribution Networks. These systems are essential for maintaining GMP compliance, supporting reliable manufacturing operations, and ensuring consistent product quality throughout the facility lifecycle. 

Pharma Access: A Pharma Turnkey Company in Andheri West

Pharma Access is headquartered at 702, Supreme Chambers, Veera Desai Road, Andheri West, Mumbai 400053. The firm has been in pharma turnkey consulting since 2001 and has delivered over 120 projects across more than 18 countries.

Their scope spans engineering design, procurement and supply, civil construction, CQV, and project management. The firm covers all major dosage forms including biotechnology, sterile manufacturing, OSD, oral liquid dosage, and API facilities.

Pharma Access holds ISO 9001:2015 (Quality Management Systems), ISO 14001:2015 (Environmental Management Systems), and ISO 45001:2018 (Occupational Health and Safety) certifications. internationally recognised management system certifications that reflect the company’s commitment to quality, environmental responsibility, and workplace safety.

Pharma Access combines multidisciplinary engineering expertise with structured project management capabilities to support pharmaceutical projects across diverse dosage forms and regulatory environments. Their team includes over 70 engineering personnel, 12 discipline subject matter specialists, and 8 technical project managers. They also developed a Modular Mobile Facility (MMF) concept, which applies prefabricated construction to pharmaceutical environments for faster project delivery.

Clients include Dr. Reddy’s, Piramal, Aragen, Al Shifa, and projects in Algeria, Saudi Arabia, Egypt, Syria, and the Middle East.

This level of scale and geographic spread is worth mentioning because it tells you the firm has managed regulatory differences, logistics complexity, and technical challenges across different markets.

How to Evaluate a Pharma Turnkey Company Before You Hire One

Next steps matter once you start comparing firms. Here is a practical checklist.

1. Ask for project references in your specific dosage category: A firm that has done 50 OSD plants but never handled a sterile injectable facility is not the right partner for your injectables project. Ask specifically.

2. Check the CQV capability: Request their standard CQV plan and ask who on the team holds the relevant qualifications. If they plan to subcontract the validation work, find out who to and what their quality standards look like.

3. Review their regulatory track record: Have they built facilities that successfully passed WHO inspections, USFDA audits, or EU GMP assessments? Ask for documented outcomes, not just claims.

4. Understand their project management method: A firm running multiple projects simultaneously needs a structured project management system. Ask how they track schedule, budget, and change orders across active projects.

5. Visit a completed facility if possible: Nothing replaces a site visit. Ask the firm to arrange a walk-through of a recently completed project. A completed facility often provides better insight into engineering quality, workmanship, and project execution than any proposal or presentation.

6. Confirm their ISO certifications are current: ISO 9001, 14001, and 45001 certifications are independently audited. Ask for the current certificate and verify the issuing body.

Andheri West vs Other Mumbai Locations for Pharma Consultancy

Some pharma turnkey firms operate from Lower Parel, BKC, or Navi Mumbai. Each has trade-offs.

BKC and Lower Parel are closer to corporate headquarters and banking, but they sit further from industrial corridors. Navi Mumbai is close to manufacturing zones like Taloja and Mahape but can be harder for international travel.

Andheri West balances proximity to the airport, access to western and central industrial corridors, and availability of technical talent from nearby residential areas like Goregaon, Malad, and Borivali. For a firm running international pharma projects, this combination works better than a purely corporate address.

Frequently Asked Questions

1. What is a pharma turnkey company, and what does it include? 

A pharma turnkey company manages the complete delivery of a pharmaceutical facility, covering design, procurement, construction, equipment installation, and validation. The client hands over the project brief, and the firm is accountable for delivering a ready-to-operate facility.

2. Why should I choose a pharma turnkey company in Andheri West specifically? 

Andheri West offers direct access to Mumbai airport, strong connectivity to Maharashtra’s pharma manufacturing clusters, a large pool of qualified engineers, and proximity to key suppliers and regulatory offices. These factors make it a practical base for firms running both domestic and international projects.

3. What regulatory standards should a pharma turnkey firm be familiar with in India? 

Any firm working on Indian pharmaceutical projects should understand Revised Schedule M requirements of the Drugs and Cosmetics Act, WHO GMP guidelines, and CDSCO requirements. For export-oriented facilities, US FDA 21 CFR Parts 210 and 211 and EU GMP Guidelines, including Annex 1 where applicable, needed.

4. How long does a pharma turnkey project typically take from design to validation? 

Project timelines depend on the type of facility. A greenfield oral solid dosage plant may take 18 to 30 months. A sterile or biotech facility often takes longer, ranging from 24 to 48 months, because of the stricter design requirements, cleanroom classifications, and validation workload.

5. What is the difference between an EPC contractor and a pharma turnkey consultant? 

An EPC (Engineering, Procurement, and Construction) contractor covers design, sourcing, and building. A pharma turnkey consultant may also include CQV, regulatory documentation support, and GMP-specific engineering that goes beyond standard civil and MEP work. The pharma-specific layer, including cleanroom design, HVAC validation, and process equipment qualification, is what separates a general EPC firm from a dedicated pharma turnkey company.

Posted on

How Mobile Racking Systems Improve Efficiency in Pharma Warehouses

How Mobile Racking Systems Improve Efficiency in Pharma Warehouses

A pharmaceutical warehouse is not a storage room. It includes active ingredients, finished drug products, and temperature-sensitive biologics that have a direct effect on patient safety. Every square meter, every access point, every storage decision, is regulatory weight.

This is where mobile racking systems come in handy. These are some of the most practical ways pharmaceutical facilities can get more out of their existing warehouse footprint while remaining aligned with Good Manufacturing Practice (GMP) compliance and Good Distribution Practice (GDP) requirements.

Let’s break it down.

What Are Mobile Racking Systems?

A mobile racking system is a storage system in which shelving units or pallet racks are mounted on motorized or mechanical carriages that move on rails mounted on the floor. Rather than having multiple permanent aisles running between static rows of racking, the whole bank of racks moves to create a single access aisle wherever the operator needs it.

If a worker needs to retrieve goods from a specific row, the adjacent rack units slide apart on their rails, creating an aisle on demand. Most systems open an aisle in 10-20 seconds. Control options range from simple push-button panels to integration with warehouse management systems (WMS).

This design eliminates the dead space that static racking provides. A typical warehouse can use up 50 to 60 percent of its floor space in aisle space alone without storing a single pallet. Mobile racking takes back that space.

Why Pharma Warehouses Have Unique Storage Demands

To understand what mobile racking systems can do, it is useful to know what makes pharmaceutical warehouse storage different from general industrial storage.

The challenge is that Pharmaceutical warehouses are subject to GMP and GDP rules that encompass everything from temperature control and humidity to product segregation, traceability, pest control, and documentation. The World Health Organization’s GDP guidance and the EU’s Good Distribution Practice requirements both require that medicines be stored under controlled conditions throughout the supply chain to ensure their safety and efficacy.

Which in practice means:

  • Clearly separated storage areas for quarantined, released, returned, and rejected materials
  • Cold chain conditions in temperature-controlled areas (typically +2 to +8°C for biologics and vaccines and +15 to +25°C for ambient pharmaceuticals)
  • FEFO inventory rotation (First Expired First Out) to prevent expired stock from entering the distribution chain
  • Real-time inventory traceability and accurate batch documentation
  • Storage area and racking structure cleaning and housekeeping records
  • Monitoring of humidity and temperature with validated equipment and documented deviations

Static shelving and fixed pallet racking can satisfy some of these needs, but they are much less space efficient and difficult to reconfigure as regulations or product lines change. Mobile racking eliminates both problems.

How Mobile Racking Systems Improve Pharma Warehouse Efficiency

1. Significant Space Gains Without New Construction

Significant Space Gains Without New Construction

The most direct benefit is the increase in storage density. The mobile racking system can significantly increase storage density compared with conventional static racking systems, depending on the facility layout and operational requirements. Some systems remove unused aisles, increasing usable storage capacity by 50 percent or more.

This is a direct financial benefit for pharmaceutical manufacturers in urban locations, leased facilities, or temperature-controlled cold rooms where every cubic meter costs significant energy and construction. Building more warehouse space is expensive and takes a lot of time. In many facilities, expanding the building footprint is not feasible, making storage optimization within the existing envelope a more practical solution.

This is particularly true for cold storage areas. Cold rooms are some of the most expensive real estate in a pharma facility to build and operate. You can get more out of that envelope without expanding it, cutting capital and operating costs.

2. Support for FEFO and FIFO Inventory Management

GMP requires pharmaceutical warehouses to manage the flow of products in and out of storage. FEFO (First Expired, First Out) and FIFO (First In, First Out) principles are applied to ensure that the products do not stay in the storage beyond their expiry date, which is a regulatory non-compliance and patient safety issue.

Mobile racking systems support these practices by providing individual access to each row. With drive-in racking, the pallets are stored in deep aisles with only the front pallet being accessible, whereas with mobile systems, the operator can open up any aisle and access any row whenever they want. This means the warehouse team can pick stock by batch number and expiry date, without needing to work around blocked lanes or physically move pallets.

Mobile racking, when used with a warehouse management system (WMS) that tracks batch numbers and expiry dates in real time, makes FEFO compliance a practical and repeatable process, rather than a manual exercise with room for error.

3. Product Segregation and Contamination Control

The different product statuses in a warehouse need to be physically separated clearly in line with GDP guidelines. Quarantined goods should not be mixed with released stock. Dedicated and clearly identifiable storage areas are required for rejected, returned, and recalled products. Temperature-sensitive and ambient products need to be zoned.

Mobile racking systems can aid in this in a confined floor space. Color coding or lockable mobile system sections can be used to give visual cues for product status areas. Different product categories can be assigned to different carriages. The physical separation is maintained regardless of how the racks move in the course of the access operations.

For high-hygiene pharmaceutical environments, stainless steel construction may be selected due to its cleanability, corrosion resistance, and compatibility with GMP cleaning procedures. It is non-reactive, non-porous, and resistant to cleaning agents routinely used in GMP areas, allowing for easy documentation of maintenance and cleaning validation.

4. Temperature Zone Efficiency in Cold Storage

Temperature Zone Efficiency in Cold Storage

Cold chain pharmaceutical products (vaccines, biologics, insulin, and associated products) need to be maintained at +2 to +8°C and kept there uninterrupted. Any excursions that are out of range will be subject to documented investigation and may result in batch rejection or recall.

Mobile racking systems are ideal for cold room and freezer environments with configurations rated for operation down to -20°C. The system reduces non-productive storage space within the cold room by minimizing permanent aisles, allowing better utilization of the refrigerated volume. Lower air volumes to condition imply better temperature distribution and less energy consumption by refrigeration equipment.

WHO GDP guidelines require cold storage areas to have backup power systems, temperature mapping that has been validated, and continuous monitoring with documented deviation responses. When properly designed and qualified, a mobile racking system can support more efficient airflow management and temperature distribution within cold storage environments, helping maintain compliance during temperature mapping and qualification activities.

5. Adaptability for Pharma Manufacturing Automation

Adaptability for Pharma Manufacturing Automation

The pharmaceutical industry is moving toward more pharma manufacturing automation in production and warehouse operations. Mobile racking systems are a natural fit for this direction, since they are designed to integrate with modern warehouse management tools.

Push-button controls, barcode-triggered aisle opening, and WMS integrations all allow the racking system to function within an automated or semi-automated warehouse without the full investment of an automated storage and retrieval system (AS/RS). For companies still operating at mid-scale, this is a practical middle ground between fully manual static storage and high-capital robotic systems.

With the growth of operations, mobile racking can be further expanded by increasing the number of carriage units, changing the rail configurations, or adding additional shelving levels without dismantling the core structure. This modular cleanrooms pharmacy design enables the facility to adapt to changing product portfolios and regulatory requirements over time.

Pharma Equipment and Manufacturing Process Design: Where Storage Fits

Warehouse design is often an afterthought in the planning of pharmaceutical facilities. The movement of raw materials, intermediates, and finished goods through the warehouse actually has a direct impact on production scheduling, batch traceability, and GMP audit readiness.

That is why when pharma equipment and manufacturing process design are done properly, warehouse layout is part of the engineering scope, not a separate procurement decision after the manufacturing areas are built. Facility design from the beginning must include racking type, aisle widths, zone designations, cleaning access, and temperature mapping points.

“Warehouse and storage design is an integrated part of the facility engineering scope,” says Pharma Access, which has over 25+ years of experience working on more than 100 pharmaceutical projects in the biotech, sterile, OSD, and API facility categories. Their end-to-end services include engineering design, procurement of pharmaceutical equipment and manufacturing infrastructure, construction and installation, and CQV (commissioning, qualification, and validation). When rack decisions are made in this broader context, the storage system meets the facility’s regulatory and operational requirements from day one, rather than being retrofitted later.

Validation and Qualification Considerations

Mobile racking systems installed in GMP-regulated facilities should be included within the overall facility qualification strategy. Depending on the warehouse classification and intended use, qualification activities may include installation verification, load testing, operational checks, cleaning procedures, maintenance requirements, and integration verification with warehouse management systems (WMS).

Proper documentation of the racking system, including load ratings, maintenance procedures, cleaning records, and qualification reports, helps support inspection readiness and long-term regulatory compliance. Incorporating these considerations during the facility design phase can reduce qualification challenges and support smoother project execution.

Considerations Before Choosing a Mobile Racking System

Considerations Before Choosing a Mobile Racking System

Mobile racking is not a must for every pharmaceutical warehouse. Here’s an easy way to figure out if it makes sense for a given facility:

Mobile racking is a great fit when:

  • Inventory volume exceeds floor space available
  • Cold room or freezer space is costly to build and operate
  • Several product categories require separate storage areas
  • FEFO compliance is hard to manage with the current static racking.
  • The facility wants to broaden its product portfolio without broadening floor space.
  • Static racking is suitable where:
  • Very high throughput. Need to access multiple aisles at the same time, all the time
  • Few SKUs are handled by the warehouse with simple rotation requirements
  • Budget considerations favor low initial capital costs

The structure of the floor also matters. Mobile racking passes concentrated loads via the carriage bases to the concrete floor. So, it is necessary to check the structural load capacity and floor levelness prior to installation. Fire suppression system layouts may also require modifications to maintain sprinkler coverage over mobile rack configurations, and should be reviewed in accordance with applicable local fire safety codes and insurance requirements..

The Role of Pharmaceutical Engineering Consultants in India

India is one of the largest exporters of finished pharmaceutical products and APIs in the world, with a plethora of facilities operating in regulatory jurisdictions like the US FDA, EU GMP, WHO, and CDSCO. In these facilities, storage and warehouse design must adhere to many overlapping sets of guidelines at the same time.

The practical advantage of this process is that there are pharmaceutical consultants in India who specialize in turnkey facility design, such as Pharma Access, based in Mumbai. They understand the local regulatory environment, have relationships with qualified equipment and racking vendors, and have documented experience with warehouse qualification to international inspection standards.

It is far more cost-effective for a manufacturer facing an EU GMP or WHO pre-qualification audit to have the warehouse racking and zone segregation design reviewed by an experienced consulting team before construction than to have to remediate after an inspection observation. Documentation packages for mobile racking must be included in the qualification file from day one and must contain load calculations, cleaning validation protocols, and GDP segregation zone maps.

Frequently Asked Questions

1. What is a mobile racking system, and how does it differ from static racking?

Mobile racking systems have shelving or pallet racks installed on motorized carriages running on rails on the floor. Aisles open on demand rather than remaining permanently available between every row. This leads to a dramatic increase in storage density, with some systems providing up to three times more pallet positions in the same floor space as static configurations.

2. Are mobile racking systems compliant with GMP and GDP warehouse requirements?

Yes, if properly specified. Mobile racking systems can be color-coded or lockable to meet GMP and GDP segregation requirements for products. Stainless steel options meet pharmaceutical surface cleanliness requirements. In addition, the facility design documentation shall address load capacity, floor strength, and fire suppression layout requirements for the system.

3. Can mobile racking systems be used in pharmaceutical cold rooms?

Yes. Mobile racking is very suitable for cold room and freezer applications, with some systems able to operate down to -20°C. Mobile racking reduces the unnecessary aisle air volume in the cold room, which contributes to a more uniform temperature distribution, thereby facilitating GDP temperature mapping and monitoring compliance.

4. How does mobile racking support FEFO inventory management in a pharma warehouse?

Mobile racking means that operators can open the required aisle on demand to access any row at any time. Unlike deep-lane drive-in racking, there is no need to move pallets to reach a particular batch number or expiry date. When using a warehouse management system that tracks expiry dates and batch numbers, FEFO rotation becomes a reliable and auditable process, rather than a manual workaround.

5. When should pharmaceutical companies involve consultants in warehouse racking decisions?

The sooner the better. The way you rack has implications for floor load calculations, fire suppression layouts, GDP zone segregation design, temperature mapping protocols, and the qualification documentation package. Having experienced pharmaceutical consultants in India or internationally involved during the facility engineering design stage and not post-construction avoids expensive design changes and helps to ensure that the storage system is inspection-ready from day one of operation.

Posted on

Complete Guide to Pharmaceutical Facility Design and Construction

Pharmaceutical Facility Design and Construction

Building a pharmaceutical plant is one of the most technically demanding construction projects in any industry. Every room, every pipe, and every air handling unit has a regulatory weight. Poor design decisions can cause months of rework, delay a product launch, or result in a failed pre-approval inspection.

This guide walks you through how pharma facility design and construction actually work, from early planning to commissioning, and what separates projects that go smoothly from those that don’t.

What Pharmaceutical Facility Design and Construction Actually Involves

Most people outside the industry think of a pharmaceutical factory as a clean, white building with people in lab coats. The truth is much more complex.

A pharmaceutical facility is a system of systems, such as HVAC, electrical, plumbing, process piping, cleanrooms, containment zones, water treatment, waste management, automation, and building structure. Each system must comply with current Good Manufacturing Practice (cGMP) requirements and interface with the other systems without introducing the risk of contamination or compliance gaps.

Here’s a regulatory baseline: the U.S. FDA’s 21 CFR Parts 210 and 211 establish minimum requirements for drug manufacturing facility design and construction. They cover everything from the finishes on floors and walls to the patterns of personnel flow and placement of equipment. The European counterpart, EU GMP Annex 1 (revised 2022), takes this same approach and applies it with particular depth to sterile manufacturing environments.

These are not optional, and they are not something you can retrofit after construction. “Whether a facility can be qualified and approved depends on design decisions made on day one.”

What Pharmaceutical Facility Design and Construction Actually Involves

Phase 1: Concept and Feasibility

Every pharmaceutical facility project begins with a product brief. 

Before any drawing is made, the project team must have clear answers to these questions:

  • What dosage forms will be manufactured at the facility? (tablets, injectables, biologics, APIs)
  • To which regulatory markets will the product be submitted? (FDA, EMA, WHO, CDSCO)
  • How often and in what quantity will it be produced?
  • Is this a new facility, an expansion of an existing facility, or an upgrade to an existing facility
  • These responses are not administrative. They directly impact the facility design, cleanroom classification, containment strategy, and utility requirements.

For example, a plant producing oral solid dosage forms (tablets and capsules) for the Indian domestic market has very different HVAC, containment, and regulatory documentation requirements than a plant producing sterile injectables for FDA submission. It is a frequent and expensive mistake to treat them as the same type of project.

The feasibility phase also includes site selection, environmental impact assessment, utility availability checks, and a preliminary cost model. Skipping or rushing this phase will result in design conflicts later that are much more expensive to fix.

Phase 2: Pharmaceutical Facility Engineering and Design

Pharmaceutical Facility Engineering and Design

This is where the project is formed on paper, long before a shovel hits the ground. Several engineering disciplines contribute to pharmaceutical facility design.

Process Design and Room Layout

The process defines the facility, the facility should not define the process. A process flow diagram (PFD) is drawn for each step in production from the receipt of raw materials to the dispatch of the finished product. This flow then dictates the layout of the rooms, with the sequence of operations designed to minimize the risk of cross-contamination and unnecessary movement of material.

Adjacency of rooms counts. Clean and non-clean areas must be separated by airlocks, pressure differentials, or both. Personnel and material flows should be designed to minimize cross-contamination risks and avoid undesirable intersections between clean and less-clean process streams. These are not preferences; they are cGMP requirements.

HVAC and Cleanroom Design

HVAC and Cleanroom Design

In a pharmaceutical facility, the HVAC system does much more than just control temperature.

 It is responsible for:

  • Controlling airborne particle levels in accordance with ISO 14644 classification standards
  •  Maintaining room pressure cascades to contain contaminant migration
  •  Providing appropriate air change rates in each classified zone
  •  Maintaining temperature and relative humidity within validated ranges
  •  Ensuring the performance of HEPA and ULPA filtration systems

The revised EU Annex 1 mandates a formal Contamination Control Strategy (CCS) document for sterile manufacturing areas linking HVAC design decisions with product contamination risk analysis. This is not a post-construction document; this is a design phase requirement.

MEP Systems: Mechanical, Electrical, and Plumbing

Utilities in pharmaceutical facilities have to meet standards far beyond normal commercial construction. Water for Injection (WFI), Purified Water (PW), clean steam, compressed air, and nitrogen systems all require specific material specifications, installation methods, and ongoing monitoring programs.

The ASME BPE standards define requirements for piping materials, weld quality, slope for drainability, and surface finish requirements for bioprocessing equipment.

Electrical systems must support hazardous-area classifications where applicable, emergency power for critical process equipment, and building management system (BMS) integration for environmental monitoring.

Quality by Design (QbD) in Facility Engineering

QbD is an ICH-endorsed approach that incorporates quality into design decisions instead of testing later. QbD, when used for facility design, refers to recognizing the design parameters that most influence product quality and exercising control over them from the beginning.

Pharmaceutical facility engineering consultants who design facilities using QbD find them easier to validate, quicker to qualify, and less likely to be cited in regulatory findings during inspections.

One of the most common reasons pharmaceutical projects experience delays, cost overruns, or validation challenges is the disconnect between engineering, construction, and qualification teams. Successful projects integrate facility engineering, execution, and CQV planning from the earliest stages of design to ensure continuity throughout the project lifecycle. 

Phase 3: Procurement and Construction

After the design is approved and released for construction, the project moves to procurement and site execution. This is where many projects waste time and money.

That’s because pharmaceutical construction is not your run-of-the-mill commercial construction. General contractors are not equipped to handle the specialized contractors, materials traceability, and installation documentation that are needed for cleanroom panel systems, HVAC ductwork, process piping, and utility systems.

In a pharmaceutical project, procurement is not just the purchase of equipment and materials, but that process also includes vendor qualification, review of certifications, and management of factory acceptance tests (FATs) on major equipment items before they depart from the manufacturer’s facility.

Good project management at this point includes tracking design changes via a formal change control process. Any change to the approved design, even if minor, such as moving a drain, must be reviewed for its GMP impact before it is implemented. Informal ‘field changes’ that do not go through this process create gaps in the documentation that surface during validation.

Phase 4: Commissioning, Qualification, and Validation (CQV)

Procurement and Construction

CQV is the formal process that connects construction completion to regulatory approval to manufacture. 

Here’s how it works in order:

The commissioning process verifies that all systems are properly installed and functioning as the engineers intended. The result is engineering documentation, test records, and punch lists.

  • Installation Qualification (IQ) is the confirmation that equipment and systems are installed according to approved specifications and vendor requirements.
  • Operational Qualification (OQ) tests the ability of equipment and systems to operate correctly over the whole operating range.
  • Performance Qualification (PQ) establishes that the entire manufacturing process, in this facility and with this equipment, consistently produces a product meeting its predetermined quality characteristics.
  • Utilities (water systems, HVAC, and clean steam) are qualified in parallel with equipment qualification. Then comes cleaning validation and process validation.

The whole CQV package is the heart of the regulatory submission. During Pre-Approval Inspections (PAIs), this documentation is reviewed by inspectors of the FDA, EMA, or other agencies. Documentation gaps in CQV are among the most common findings during Pre-Approval Inspections (PAIs), even when the physical facility itself appears compliant.

Turnkey Pharma Facility Projects: What They Actually Deliver

A turnkey pharma facility project has one team to look after the whole scope: design, procurement, construction, and CQV. This is not like hiring a design firm, another contractor, and an independent validation consultancy and hoping they will all work together.

The turnkey model’s practical advantage is continuity. The documentation trail is unbroken when the same team that designs the HVAC system also commissions and qualifies it. Validation protocols are based directly on the design intent. The team knows where all the design decisions came from and why.

Pharma Access has completed turnkey pharmaceutical facility projects in over 18 countries, including biotech, sterile manufacturing, oral solid dosage, and API facilities. The team consists of pharmaceutical facility engineering consultants working from process design through CQV, which means clients get one accountable team and not a broken chain of vendors pointing fingers at each other when things go wrong.

Greenfield vs. Brownfield: Which Is Right for Your Project?

  • Greenfield projects are built on new land without any existing structure. They allow the most design freedom but also take the most time. You need to do site preparation, civil works, and construction sequentially before you can start manufacturing.
  • Brownfield projects are expansions or upgrades to existing facilities. They speed things up but bring limitations: existing column grids, ceiling heights, utility entry points, and the need to keep ongoing manufacturing operations running during construction.
  • The decision depends on the timeline, budget, site availability, and whether existing infrastructure can meet the technical requirements of the new project. During the feasibility period, pharmaceutical facility engineering consultants review both options and recommend the one most consistent with the client’s production schedule and capital budget.

FAQs

1. How long does pharmaceutical facility design and construction take from start to finish?

A typical greenfield pharmaceutical facility will take three to five years from concept approval to first product batch. This includes design (6-12 months), construction (12-24 months), and CQV (12-18 months). Under good conditions, modular construction approaches can shorten this timeline by twelve to eighteen months.

2. What is the difference between GMP design and standard commercial construction?

GMP design translates regulatory requirements into the physical aspects of each facility, including room finishes, airlock design, pressure differentials, utility systems, and personnel flows. Standard commercial construction meets the building codes but has no equivalent documentation, traceability, or validation requirements.

3. What cleanroom classification does my pharmaceutical facility need?

That depends on the product and the manufacturing step. Oral solid dosage facilities often operate in controlled but non-aseptic environments, Aseptic fill-finish operations require an ISO Class 5 (Grade A) at the point of exposure within an ISO Class 7 (Grade B) background. Your pharmaceutical facility engineering team should define classifications based on the contamination risk profile of the product and the intended regulatory market.

4. What does a pharmaceutical facility engineering consultant actually do?

Pharmaceutical Facility Engineering Consultants • Process Design • Room Layout • HVAC • MEP and Utilities Design Often combined with equipment selection, vendor management, construction supervision, and CQV. The scope depends on the project, but the best consultants will take the facility from concept drawings to regulatory approval, not hand off mid-project.

5. What is the role of pharmacy consultancy services in a facility project?

Pharmacy consultancy services offer regulatory and technical expertise for facility projects, assisting clients in making design decisions compliant with current GMP standards in their chosen markets. Good pharmacy consultancy services identify regulatory risks early, before construction locks in decisions that are costly to reverse.

Posted on

Who Delivers Leading Pharmaceutical Facility Design Solutions for Modern Pharma Plants?

Pharmaceutical Facility Design Solutions for Modern Pharma Plants

The Standard for Modern Pharma Facilities Has Changed

In 2024, the worldwide pharmaceutical manufacturing market was valued at around $589 billion. By 2033, that number is expected to continue growing significantly, driven by expanding pharmaceutical capacity, biologics, and regulated manufacturing demand. Investors are pouring money into reimagining how pharmaceutical manufacturing facilities are built and what they look like.

Between 2024 and 2030, several leading pharmaceutical manufacturers have announced large-scale investments in manufacturing expansion, fill-finish capacity, biologics, and advanced production infrastructure.

The massive influx of capital raises an important question. Who can actually deliver the pharmaceutical facility design solutions required to build and operate modern pharma manufacturing facilities that meet today’s technical, regulatory and operational demands? What separates those who help manufacturers remain inspection-ready from day one?

Let’s take an objective look at what sets the best pharmaceutical facility design companies apart, and what every pharmaceutical manufacturer should look for in a design partner. 

What Modern Pharmaceutical Facility Design Actually Requires

Starting with the Product, Not the Building

One of the most common mistakes in designing a pharmaceutical plant is to focus on the building itself as the centerpiece of design. The facility should be built around the process, and the process is driven by the product.

Sterile injectables require an entirely different facility design than oral solid dosages. Biotech manufacturing, such as monoclonal antibodies, requires strict contamination-control and process-specific design considerations that are not the same as those used in tablet plants. And API synthesis plants need unique chemical handling facilities, fume extraction systems, and waste treatment systems that oral dosage forms do not.

World-class pharma plant design services will start with a User Requirement Specification (URS) that translates the product type, dosage form, process, batch size, and target markets into a master list of facility requirements prior to any layout drawings being created. Every subsequent design decision from room classification to HVAC loads to material flow to utility routing to equipment footprint can be traced back to the requirements created from that URS.

Pharma engineering services that do not take the time to develop this foundation may create facilities that look compliant on paper but become difficult to operate consistently in practice: contamination excursions, failed EM tests, inadequate containment, or undersized utility systems. 

Cleanroom Design as an Engineering Discipline

Cleanrooms are often classified under ISO 14644-1. This standard gives specifications for Class 1 through Class 9 cleanrooms based on the number of particles permitted per cubic meter of air. Regulatory frameworks such as EU GMP Annex 1 and FDA cGMP expectations add requirements beyond particle classification, especially for sterile pharmaceutical manufacturing environments. These include: microbiological levels, pressure relationships, growing standards and environmental monitoring frequencies.

Simply stated, classification of the cleanroom dictates:

  • The number of air changes per hour required to maintain the desired cleanliness level, based on process risk, occupancy, recovery time, and heat load
  • Filtration (HEPA H14, 99.995% at MPL) meets most needs for ISO Class 5 through ISO Class 8 rooms)
  • Pressure relationship to other areas through a designed pressure cascade that supports contamination control
  • Hard surface finishes that are smooth, non-shedding, resistant to chemicals & cleaning agents and are easily cleaned
  • Airlocks when entering or exiting areas of different ISO class

Over-classifying cleanrooms can add significant capital and operating cost. Opting for a lower cleanroom rating can result in failure to meet regulations. Cleanroom design isn’t guessing at the ISO rating that a room should be based on an iso classification chart. It should be based on what the process can actually tolerate. This means knowing your process and your products. 

HVAC: The System That Makes or Breaks Everything Else

HVAC systems in pharmaceutical manufacturing facilities are not “building services.” They are process-critical systems that answer the question of whether a cleanroom can maintain its classification; whether temperature and humidity conditions are stable enough to ensure product quality; and whether pressure differentials between adjacent “cleanrooms” or “zones” stay within validated limits 100% of the time. Pharmaceutical cleanrooms can use significantly more energy than typical commercial buildings, and HVAC systems account for over 50% of the electricity consumed. 

Qualification of HVAC systems including HEPA filter integrity testing, air flow volume and velocity mapping, room pressure differential confirmations, temperature and humidity control and monitoring, and ISO particle counts should be performed, documented, and approved before any manufacturing activity begins, and trended at scheduled intervals throughout product manufacture. While 21 CFR 211.42 does not prescribe a specific HVAC qualification protocol, it requires facilities to be designed and operated to prevent contamination and mix-ups. In practice, this makes HVAC design, qualification, monitoring, and documentation critical parts of GMP compliance. 

When inspectors review HVAC systems, they specifically look for HVAC validation records, environmental monitoring trends, and HVAC deviation investigations. Sites that cannot provide a complete HVAC qualification dossier may face regulatory observations or delays during approval. 

Pharma engineering services groups tasked with designing HVAC systems for drug manufacturing facilities should understand the regulations and qualification process as well as the operating parameters: energy costs, required redundancies, maintenance access, and future expansion. 

What Separates Strong Pharma Facility Design Companies from the Rest

Compliance Embedded from Day One

The single biggest factor when choosing between pharma facility design firms is whether they view regulatory compliance as a design input or design output. When compliance is treated as an output, facilities may face late-stage documentation gaps, redesign work, and qualification challenges.

When compliance is treated as an input, every decision—room layout, routing of utilities, machine and equipment placement, specification of surfaces, and sizing of airlocks—is made with one question in mind: does this support the qualification process and the inspection outcome the manufacturer needs? Qualification documentation created throughout engineering and construction becomes your inspection ready foundation, rather than a separate project done in panic weeks before the FDA shows up.

This is known in the industry as commissioning, qualification and validation focused design or CQV for short. CQV requirements are designed into the engineering so that the physical facility and documentation package are developed hand in hand. 

Quality by Design Applied to the Facility

ICH Q8(R2) defines Quality by Design (QbD) as an approach to pharmaceutical development where the quality of the product is built into the design of the product and its manufacturing process. Although ICH Q8(R2) focuses on pharmaceutical development, the same principle is highly relevant to facility design.

When QbD principles are applied to facility engineering, the critical quality attributes (attributes of the manufactured product that must be maintained to ensure product safety and efficacy) are linked to facility design decisions that control them. Air classification, pressure differentials, temperature control ranges, and contamination barrier designs are selected and documented based on the risks to product quality, rather than because they were included in the last facility your designer worked on.

Facility design solutions that start with QbD create facilities that are easier to validate, easier to operate within specification, and stand up better to regulatory scrutiny because there is a clearly documented reason for every decision that relates back to product quality. 

The Turnkey Advantage: Coordinated Delivery Across All Disciplines

Conventional pharma plant construction divides the scope among an architect, process engineer, MEP contractor, equipment supplier, validation team. They each design from their scope, hand off to the next player, and may not always carry full accountability for how their discipline interfaces with the others. The consequence is mismatched interfaces, rework, validation delays, and schedule headaches.

Turnkey solutions bring unity to the project by placing responsibility under one delivery partner. Design, procurement, construction, installation, commissioning, qualification, and validation are executed under one coordinated plan. Integration of process engineering, cleanroom design, HVAC, electrical, utilities, and automation is coordinated from the start in the engineering stage, preventing delays and conflicts during construction and validation.

The advantages turn into tangible value. Prefabricated cleanroom systems and modular construction methods can reduce on-site work by shifting fabrication, integration, and quality checks into a controlled factory environment. Turnkey partners who use well-planned modular approaches can help shorten project timelines when site readiness, regulatory scope, and engineering coordination are aligned. When speed to market is a pharmaceutical manufacturer’s need to meet competitive or regulatory demands for new capacity, every month matters. 

What to Look For in a Pharmaceutical Facility Design Partner

ENGINEERING – what differentiates a true pharmaceutical facility design partner from your run-of-the-mill engineering firm that “does pharma work”:

  • Experience with multiple dosage forms: Cross-pollination between projects for sterile injectable facilities, biotech plants, oral solid dosage facilities and API facilities breeds a knowledge base that narrow-focused specialists will never match. Lessons learned from contamination control in a biotech suite will influence your airlock designs in an OSD facility. Experience with utility systems in an API plant will define the envelope of what can be achieved when designing a future sterile expansion project.
  • Design that incorporates CQV: Your qualification documentation should be a designed deliverable, not something your engineers “figure out” later. Inquire specifically if the design engineers and qualification specialists are working together from the URS stage forward.
  • International regulatory knowledge: A facility designed to meet regulatory requirements in one country will face hurdles when seeking approvals in the US, EU, or any regulated market outside their native region. FDA 21 CFR Parts 210 & 211, EU GMP Annex 1, WHO-GMP, PIC/S…they are all written differently, yet each contains unique facility design expectations that should be addressed during engineering.
  • Prefabrication expertise: The capability to build cleanroom modules, utility skids, and process equipment off-site while civil and structural work is performed on-site is a project delivery expertise that translates into tangible schedule and cost savings.

Pharma Access is that unique combination of skills applied to pharmaceutical facilities. “We’ve been around for 25 years, completed over 100 projects and have facilities in 18 countries,” says Kumar Advani, President and Founder of Pharma Access. “We provide full engineering design, procurement, construction, installation, commissioning, qualification and validation. 

We do it all.” Pharma Access’ experience includes biotechnology facilities, sterile manufacturing facilities, oral solid dosage (OSD) facilities, oral liquid dosage (OLD) facilities, and API facilities. Across these manufacturing formats, Pharma Access brings integrated design-and-build experience for complex pharmaceutical environments.

Pharma Access has now combined that turnkey expertise with prefabricated construction methods through their Modular Mobile Facility (MMF) platform. The MMF platform allows Pharma Access to apply the efficiencies of factory controlled construction to drastically reduce on-site assembly time while limiting CO2 emissions and maximizing the engineering required for GMP compliance.

FAQs: Pharmaceutical Facility Design Solutions

Q1: What is included in pharmaceutical facility design solutions? 

Pharmaceutical facility design solutions cover the full scope of engineering required to deliver a GMP-compliant manufacturing plant. This includes process design, cleanroom layout and classification, HVAC and MEP systems design, utility systems such as water for injection, clean steam, purified water, and compressed air where applicable, civil and structural design, automation and building management systems, and commissioning, qualification, and validation planning and execution.

Q2: How do pharma facility design companies decide what cleanroom classification a room needs? 

Cleanroom classification is determined by the product being manufactured and the operations taking place in the room. Sterile fill/finish operations typically require ISO Class 5 environments at the point of critical operation, supported by appropriate background classifications depending on the process and regulatory expectation. . Support areas may be classified at ISO Class 7 or ISO Class 8. The design firm works from the User Requirement Specification to map each room’s function to the appropriate ISO 14644-1 class, then designs HVAC, filtration, and monitoring systems to maintain that class.

Q3: What is a turnkey pharmaceutical plant solution and how does it differ from conventional project delivery? 

A turnkey pharmaceutical plant solution places complete project responsibility design, procurement, construction, qualification, and validation with a single partner. Conventional delivery splits these responsibilities across multiple contractors. The turnkey model eliminates interface risk between disciplines, produces more consistent documentation, and typically delivers faster completion timelines with better alignment between facility design and regulatory requirements.

Q4: How does cleanroom design for pharmaceuticals differ from cleanroom design in other industries? 

Pharmaceutical cleanroom design must meet both ISO 14644-1 particle classification standards and GMP regulatory requirements covering microbiological limits, pressure differentials, environmental monitoring, gowning procedures, and qualification documentation. The FDA and EU GMP authorities inspect these systems and review qualification records. Non-pharmaceutical cleanrooms are typically focused more heavily on particle control, while pharmaceutical cleanrooms must also address product safety, contamination control, patient risk, and GMP documentation.

Q5: Why does HVAC design matter so much in pharmaceutical plant design services? 

HVAC systems directly determine whether a cleanroom holds its ISO classification, whether temperature and humidity conditions protect product stability, and whether pressure differentials between zones prevent contamination migration. HVAC qualification is a key GMP expectation linked to contamination control and facility performance, and HVAC records are reviewed in FDA inspections. An undersized, poorly designed, or inadequately qualified HVAC system can render an otherwise compliant facility unable to pass inspection.

Posted on

Challenges in Setting Up Pharmaceutical Plants in Saudi Arabia

pharmaceutical plants in Saudi Arabia

Saudi Arabia boasts the largest pharmaceutical market in the Middle East and North Africa region. Despite this, the Kingdom imports most of its medicines. All that is set to change – Vision 2030 is striving to localize pharmaceutical production. Saudi Arabia wants to increase local pharmaceutical manufacturing from an estimated 20% to 40% of the market supply. To support local production, the Kingdom allocated USD 65 billion to improve its healthcare system.

This signals a significant and urgent opportunity for business. However, there are some significant and urgent challenges any business will face when constructing a pharmaceutical plant in Saudi Arabia. Here are some things to know beforehand. 

SFDA Compliance Is Demanding

The Regulatory Hurdle: SFDA Compliance Is Demanding

The first hurdle that greets any plant developer is the Saudi Food and Drug Authority (SFDA). Created in 2003 it regulates drug registration, pricing, manufacturing licenses, facility inspections and key stages of the pharmaceutical value chain, from API production to distribution. Manufacturers must adhere to GMP rules based on WHO and PIC/S guidance. The SFDA will perform its own inspections as needed but may accept certification by another trusted regulatory body. Drug registration is completed through the Drug Registration System via the Common Technical Document (CTD) format and follows ICH guidelines. Products cannot be sold without valid approval from the SFDA.

This is typically the step that creates delays for many projects. The approval process is lengthy if you’re submitting a new product or generic to enter the market for the first time. Requirements for API manufacture are extensive and variations between Saudi local norms vs. international expectations create gaps that slow down product approval timing.

As of January 2025, SFDA has made new economic evaluation requirements  applicable. Full economic evaluations were enforced starting July of 2025. Essentially this requires manufacturers to produce clinical and economic data relevant to the Saudi population in support of your submission. This factor alone significantly increases both cost and timing for getting a new build facility ready for market.

The easiest way to overcome these challenges is by partnering with knowledgeable pharma GMP consulting experts in Saudi Arabia at the outset of your project, not after construction has completed.

Cleanroom Design in a Desert Climate

Cleanroom Design in a Desert Climate

Pharma manufacturing by its nature is conducted in highly controlled environments. Oral solid dosage, sterile injectable and biologics cleanrooms run precise temperature, humidity and particulate controls 24/7.

That’s easy to say, but Saudi Arabia is hot, with summer temperatures often reaching above 45°C and windy. Sand and dust are a year-round contamination concern. HVAC engineers building pharmaceutical facilities in Saudi Arabia have some of the toughest make-up air conditions in the world. They are managing extreme heat, dust exposure, and demanding outdoor air conditions while trying to maintain ISO room pressurization, air change per hour (ACH) rates and temperature ranges.

There are pharmaceutical specific manufacturing districts being built by MODON (Saudi Authority for Industrial Cities and Technology Zones) with full infrastructure; cleanroom facilities, QA labs, warehousing designed to support international GMP expectations. The MEP design and engineering of these facilities is up to the individual project teams.

Specification of the correct cleanroom materials, AHUs and redundant systems should be engineered by a team with experience in the region. region-specific HVAC, filtration, and GMP design expertise.

Sourcing Qualified Contractors and Skilled Workforce

Saudi Arabia enforces a Saudization mandate (locally known as Nitaqat), which specifies minimum percentages of Saudi nationals that make up the workforce of any company. Pharmaceutical manufacturing requires specialist knowledge at all levels, from process engineers and validation specialists down to QC analysts and cleanroom technicians. The challenge of finding qualified Saudi nationals to staff these roles is very real, and programs to train people up will take time.

Similarly, recruiting and keeping international pharma engineers with experience in plant setup projects is not without its challenges of work visas, expat housing, and project timelines.

The local contractor market for pharma-ready construction is also somewhat shallow compared to seasoned manufacturing destinations like India or Europe. While there are vendors familiar with cleanroom panel systems, pharma HVAC specs, GMP documentation requirements, etc., picking the right ones and managing the supply chain demands competent project management from teams with pharma-sector experience.

Partnering with a Saudi Arabia-focused pharma turnkey solutions provider early, before the process of contractor selection begins, allows the project team to qualify local vendors, determine gap areas, and plan for technology transfer where necessary.

Sourcing Qualified Contractors and Skilled Workforce

Technology Transfer and Local Content Requirements

Vision 2030 doesn’t just want pharmaceutical plants constructed in Saudi Arabia. Vision 2030 wants technology transfer, localization of capabilities, and contributions to long-term national self-sufficiency. This places tremendous pressure on foreign investors and international manufacturers to shape joint ventures, training programs, and procurements through local suppliers.

The National Unified Procurement Company, or NUPCO, has been a dominating force in the Saudi Pharma supply chain since 2009. The government conglomerate currently holds procurement sway over much of the public sector. Finding product pipeline alignment with NUPCO’s procurement needs is a strategic move that should be decided upon well before your plant is registered, not after.

Technology transfer considerations for biologics and vaccine manufacturers will be even more nuanced. The domestic manufacturing capability for biologics within the Kingdom is currently still developing compared with mature global manufacturing hubs. Vision 2030 has publicly made this sector a target for growth. The KSA has taken action through the launch of the Saudi Vaccine and Biologics Manufacturing Company, as well as international partnerships with CDMOs. Investors looking to break into this sector should expect a longer timeline and more intricate technical transfer process.

Infrastructure and Site Selection Constraints

Site selection is typically driven by the availability of land. Facility viability is impacted by reliable water sources, stable power grids, logistical access and access to cold-chain infrastructure. Saudi Arabia has several industrial cities with robust infrastructure, logistical network and municipality utilities supported by MODON. Sudair, around 120 kilometres north of Riyadh is one such city. It is emerging as an important location for pharma-grade manufacturing facilities.

The timeline to market for a vaccine or injectable manufacturing plant in Saudi Arabia is generally between 24-36 months. This includes time to select a site, complete design, construct and validate the facility. Each step in the process has its own potential setbacks be it delayed regulatory approval, construction delays, or commissioning delays of machinery and equipment. These setbacks are cumulative and impact the total project costs as well as time to revenue.

Pharma turnkey solution contracts are becoming more popular in Saudi Arabia. This methodology uses one team to design, procure, construct and commission the facility under one contract.

GMP Documentation and Validation

GMP Documentation and Validation

Constructing a pharma plant is only part of the equation. Before that first production batch rolls off line at a Saudi plant, the facility itself must pass SFDA GMP inspection, and every process system from HVAC to water for injection to process equipment must be qualified and validated according to defined criteria and procedures.

The SFDA has been enhancing its pharmacovigilance capabilities in recent years, as well as putting into place risk-based inspection frameworks. It has also increased the number of GMP inspectors qualified to inspect both local and foreign facilities. The country became a member of the Pharmaceutical Inspection Co-operation Scheme, or PIC/S, in 2023, strengthening alignment with international inspection standards.

That means documentation requirements are increasing. URSs, FAT, IQ, OQ, and PQ protocols must all be created, executed, and archived in a manner that passes SFDA muster. Incomplete documentation is one of the most frequent causes for inspection delays.

Pharma Access (pharmaaccess.net) provides Commissioning, Qualification, and Validation (CQV) as part of its portfolio of pharma turnkey engineering services. Incorporating that knowledge into the project plan from day one eliminates the expensive remediation that comes from approaching validation as a step to be considered at the end of construction.

Bringing It Together: What Successful Projects Have in Common

Projects that are delivered on time and pass SFDA inspection “right of first review” tend to have a couple things in common. They hire pharma consulting Saudi Arabia and pharmaceutical engineering services Saudi Arabia early. They select pharma turnkey solutions partners with actual GMP facility experience in-country. They approach regulatory strategy, cleanroom design, and workforce development as integrated efforts.

Pharma Access has 25+ years of experience completing projects in 18+ countries, including experience in the MENA region. With experts in Pharma engineering design, design/build, project management, and CQV, Pharma Access has what it takes to assist your company’s next pharmaceutical manufacturing investment in Saudi Arabia.

There is a real opportunity in Saudi Arabia. So are the challenges that must be addressed with the right expertise. However, with the right team advising you day one, the difference between a streamlined project versus one that costs you time and money becomes self-evident.

FAQs

Q1: What regulatory approval is needed to manufacture pharmaceuticals in Saudi Arabia? 

Any pharmaceutical manufacturer operating in Saudi Arabia must obtain a manufacturing license from the Saudi Food and Drug Authority (SFDA). Products must also be registered using the CTD format through the SFDA’s Drug Registration System. Manufacturers must meet GMP guidelines based on WHO and PIC/S standards, and be prepared for SFDA facility inspections before and after commercial operations begin.

Q2: How long does it take to set up a pharmaceutical manufacturing facility in Saudi Arabia? 

A typical pharmaceutical manufacturing facility in Saudi Arabia, from site acquisition through design, construction, and validation, takes approximately two to three years to complete. Biologics and sterile injectable facilities may take longer due to greater technical complexity and more demanding qualification requirements. Early planning and experienced project teams reduce the risk of delays.

Q3: What are the cleanroom design challenges specific to Saudi Arabia? 

Saudi Arabia’s extreme summer heat and persistent desert dust create demanding conditions for cleanroom HVAC systems. Air handling units must maintain GMP-compliant temperature, humidity, and pressure conditions while working against outdoor ambient temperatures exceeding 45°C. Redundant systems and robust filter management are not optional in this climate.

Q4: Does Vision 2030 offer any benefits for pharmaceutical manufacturers in Saudi Arabia? 

Vision 2030 supports pharmaceutical manufacturers through incentives including streamlined approvals for locally produced products, tax and customs exemptions in some cases, and access to MODON-administered industrial zones with purpose-built GMP infrastructure. The program actively encourages technology transfer, joint ventures, and local workforce development, creating a range of partnership opportunities for international manufacturers.

Q5: Why should I use a pharma turnkey solutions partner for a Saudi Arabia project? 

A pharma turnkey solutions Saudi Arabia partner manages engineering design, procurement, construction, and commissioning as one coordinated effort. This reduces interface risk between contractors, keeps documentation aligned with SFDA requirements throughout the project, and brings specialized GMP and cleanroom design experience that generalist construction firms do not have. It also puts responsibility for delivery on one accountable team.